Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
Clodagh Towns(National Hospital for Neurology and Neurosurgery), Tarek Antar(National Institutes of Health), Kristin Levine(National Institutes of Health), Julie Joubert(King's College London), Madeleine Richer(King's College London), Hampton L. Leonard(National Institutes of Health), Bradford Casey(Michael J. Fox Foundation), Claire Wegel(Indiana University School of Medicine), Mary B. Makarious(National Institutes of Health), Manuela Tan(Oslo University Hospital), Laurel A. Screven(National Institutes of Health), Alejandro Martínez-Carrasco(King's College London), Eleanor J. Stafford(King's College London), Cornelis Blauwendraat(National Institute of Neurological Disorders and Stroke), Huw R. Morris(University College London), Caroline B. Pantazis(National Institute of Neurological Disorders and Stroke), Dan Vitale(National Institutes of Health), Hirotaka Iwaki(National Institute of Neurological Disorders and Stroke), Andrew Singleton(Short and Associates (United States)), Dena G. Hernandez, Simona Jasaityte(King's College London), J Solle(Michael J. Fox Foundation), Mike A. Nalls(National Institutes of Health)
Cited by 3
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k